Tango Therapeutics, Inc. 8-K

What Happened
Tango Therapeutics (TNGX) filed an 8-K reporting that its board determined Daniella Beckman would no longer serve as Chief Financial Officer effective April 15, 2026, and that her last day of employment was May 1, 2026. On May 7, 2026, the company and Ms. Beckman entered into a Separation Agreement and Release that defines severance, benefits and equity treatment in connection with her departure.

Key Details

• The Separation Agreement provides 12 months of severance pay at Ms. Beckman’s current base salary, paid in substantially equal installments over 12 months.
• The company will reimburse monthly COBRA premiums for up to 12 months.
• The company agreed to accelerate vesting of the portion of Ms. Beckman’s outstanding options and restricted stock units that would have vested had she remained employed for an additional 24 months following May 1, 2026.
• The post‑termination exercise period for any of her vested stock options is extended through August 31, 2026. Ms. Beckman signed a general release to receive these benefits. The Separation Agreement is attached as Exhibit 10.1 to the filing.

Why It Matters
This 8-K documents a material finance leadership change at Tango (the CFO role) and confirms the company will incur severance and equity-related obligations tied to the departure. Investors should note the agreement’s compensation and equity provisions (severance, COBRA reimbursement, accelerated vesting, extended option exercise window) as they may affect near‑term compensation expense and the timing of potential option exercises or RSU settlements.